Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $6.7 million.

  • Catalyst Pharmaceuticals' Other Working Capital Changes rose 22963.61% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year increase of 12023.97%. This contributed to the annual value of $11124.0 for FY2024, which is 9980.79% down from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Other Working Capital Changes of $6.7 million as of Q3 2025, which was up 22963.61% from $7.4 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' Other Working Capital Changes' 5-year high stood at $9.8 million during Q2 2024, with a 5-year trough of -$7.0 million in Q1 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' median Other Working Capital Changes value was $752500.0 (recorded in 2021), while the average stood at $1.0 million.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first surged by 189480.52% in 2022, then tumbled by 68016.53% in 2025.
  • Catalyst Pharmaceuticals' Other Working Capital Changes (Quarter) stood at -$77000.0 in 2021, then soared by 1894.81% to $1.4 million in 2022, then plummeted by 203.26% to -$1.4 million in 2023, then surged by 286.05% to $2.7 million in 2024, then soared by 152.24% to $6.7 million in 2025.
  • Its last three reported values are $6.7 million in Q3 2025, $7.4 million for Q2 2025, and -$7.0 million during Q1 2025.